Broad neutralization of SARS-related viruses by human monoclonal antibodies
…, E Laudermilch, C Florez, JM Fels, CM O'Brien… - Science, 2020 - science.org
Broadly protective vaccines against known and preemergent human coronaviruses (HCoVs)
are urgently needed. To gain a deeper understanding of cross-neutralizing antibody …
are urgently needed. To gain a deeper understanding of cross-neutralizing antibody …
Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody
…, TJ Yockachonis, AS Herbert, MB Battles, CM O'Brien… - Science, 2021 - science.org
The recurrent zoonotic spillover of coronaviruses (CoVs) into the human population
underscores the need for broadly active countermeasures. We employed a directed evolution …
underscores the need for broadly active countermeasures. We employed a directed evolution …
Structural and mechanistic basis of neutralization by a pan-hantavirus protective antibody
…, C Florez, LC Polanco, CM O'Brien… - Science translational …, 2023 - science.org
Emerging rodent-borne hantaviruses cause severe diseases in humans with no approved
vaccines or therapeutics. We recently isolated a monoclonal broadly neutralizing antibody (…
vaccines or therapeutics. We recently isolated a monoclonal broadly neutralizing antibody (…
Human antibody recognizing a quaternary epitope in the Puumala virus glycoprotein provides broad protection against orthohantaviruses
…, J Wigren-Byström, LC Polanco, CM O'Brien… - Science translational …, 2022 - science.org
The rodent-borne hantavirus Puumala virus (PUUV) and related agents cause hemorrhagic
fever with renal syndrome (HFRS) in humans. Other hantaviruses, including Andes virus (…
fever with renal syndrome (HFRS) in humans. Other hantaviruses, including Andes virus (…
A combination of receptor-binding domain and N-terminal domain neutralizing antibodies limits the generation of SARS-CoV-2 spike neutralization-escape mutants
Most known SARS-CoV-2 neutralizing antibodies (nAbs), including those approved by the
FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain (RBD) …
FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain (RBD) …
Optimization of Isothiazolo[4,3-b]pyridine-Based Inhibitors of Cyclin G Associated Kinase (GAK) with Broad-Spectrum Antiviral Activity
…, R Barouch-Bentov, LI Prugar, CM O'Brien… - Journal of medicinal …, 2018 - ACS Publications
There is an urgent need for strategies to combat dengue and other emerging viral infections.
We reported that cyclin G-associated kinase (GAK), a cellular regulator of the clathrin-…
We reported that cyclin G-associated kinase (GAK), a cellular regulator of the clathrin-…
[HTML][HTML] Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein
…, E Laudermilch, C Florez, JM Fels, CM O'Brien… - BioRxiv, 2020 - ncbi.nlm.nih.gov
Broadly protective vaccines against known and pre-emergent coronaviruses are urgently
needed. Critical to their development is a deeper understanding of cross-neutralizing antibody …
needed. Critical to their development is a deeper understanding of cross-neutralizing antibody …
[HTML][HTML] An engineered antibody with broad protective efficacy in murine models of SARS and COVID-19
…, TJ Yockachonis, AS Herbert, MB Battles, CM O'Brien… - BioRxiv, 2020 - ncbi.nlm.nih.gov
The recurrent zoonotic spillover of coronaviruses (CoVs) into the human population underscores
the need for broadly active countermeasures. Here, we employed a directed evolution …
the need for broadly active countermeasures. Here, we employed a directed evolution …
A combination of RBD and NTD neutralizing antibodies limits the generation of SARS-CoV-2 spike neutralization-escape mutants
…, ME Dieterle, AZ Wec, CM O'Brien, M Sakharkar… - bioRxiv, 2021 - biorxiv.org
Most known SARS-CoV-2 neutralizing antibodies (nAbs), including those approved by the
FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain (RBD) …
FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain (RBD) …
Animal Model Prescreening: Pre-exposure to SARS-CoV-2 impacts responses in the NHP model
…, TL Clements, CJ Shoemaker, AI Kuehne, CM O'Brien… - bioRxiv, 2020 - biorxiv.org
COVID-19 presents herculean challenges to research and scientific communities for producing
diagnostic and treatment solutions. Any return to normalcy requires rapid development of …
diagnostic and treatment solutions. Any return to normalcy requires rapid development of …